TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Histologic or cytologic diagnosis of small cell lung caner(SCLC), Extensive Stage.~Previous treatments including first-line therapy with EP or CE and second-line therapy with topotecan; Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2; Males or females between 18 Years to 75 Years. Expected survival is above three months. At least one measurable lung tumor lesion (according to RECIST criteria, the application of conventional technology, diameter length of the lesion \>= 20mm or spiral CT \>=10mm).~Adequate hematologic (Leukocyte count \>= 4.0×109/L, neutrophil count\>=2.0×109/L, hemoglobin\>=95g/L, platelets\>=100×109/L), hepatic function (aspartate transaminase (AST) \& alanine transaminase(ALT) =\<upper normal limit(UNL) x1.5, bilirubin level =\< UNL x 1.5).~Patient can take oral medicine. Patients have the ability to understand and voluntarily sign the informed consent, and allow adequate follow-up.~Exclusion Criteria:~History of cardiovascular disease: congestive heart failure (CHF) \> New York Heart Association (NYHA) II, active coronary artery disease(patients with myocardial infarction six months ago can be recruited), arrhythmias need to be treated (allow taking beta blockers or digoxin).~Serious clinical infection (\> NCI-CTCAE version 4.0 ,infection standard II). Patients with epilepsy who need to take medicine (such as steroids or anti epilepsy agents).~The patients had accepted allogeneic organ transplantation. Bleeding tendency or coagulation disorders. Patients who need renal dialysis. Suffered from other tumor within 5 years( Except: cervical carcinoma in situ, cured basal cell carcinoma, cured bladder epithelial tumor).~Uncontrolled hypertension (systolic pressure\>150 mmHg , or diastolic pressure\> 90 mmHg).~Thrombosis or embolism(cerebrovascular accidents including transient ischemic attack within the last 6 months).~Pulmonary hemorrhage \>CTCAE grade 2 within 4 weeks before first use of drugs. Other organ hemorrhage \>CTCAE grade 3 within 4 weeks before first use of drugs. severe uncured wounds, ulcers or fracture. uncured dehydration. Factors influencing the safety and compliance of patients. Inability to comply with protocol or study procedures. Pregnant or breast-feeding. The researcher believe that the Patient is not suitable to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- refractory SCLC (Type: EXPERIMENTAL): Patients receive apatinib 500mg/d until progressive Disease(PD).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* receiving stable dose of oral ropinirole or pramipexole whose symptoms are not optimally controlled or whose oral dopamine agonist titration regimen was truncated due to intolerability:~* 1) Minimum dose of agonist will be 6 mg/day for ropinirole and 1.0 mg/day for pramipexole~* 2) Stable dopamine agonist treatment must have been ongoing for ≥ 30 days, no longer than 5 years preceding baseline~* Males and females. Women of childbearing potential must agree to practice an acceptable method of birth control.~* Idiopathic Parkinson Disease confirmed at baseline by presence of at least 2 cardinal signs (resting tremor, bradykinesia, rigidity), w/o other known or suspected cause of Parkinsonism~* Hoehn \& Yahr \> 1 (symptoms on only one side of the body) with treatment and \< 3 (mild to moderate bilateral disease; some postural instability; physically independent).~* Dopamine agonist dose must be stable for ≥30 days preceding the baseline visit.~* For patients who are receiving amantadine or anticholinergics, the dose must have been stable for ≥30 days prior to screening.~* Medically stable outpatients (Investigator's judgment).~Exclusion Criteria:~* receive rasagiline or other monoamine oxidase (MAO) inhibitors 60 days preceding baseline~* receive levodopa \> 21 consecutive days within 90 days prior baseline~* moderate to severe motor fluctuations~* hepatic impairment~* investigational medications 30 days preceding baseline~* dopamine agonist use \> 5 years prior to baseline~* major depression as defined by Beck Depression Inventory (BDI) short form score greater than 14~* significant cognitive impairment as defined by Mini-Mental State Exam (MMSE) score less than 26.~* impulse control disorder (ICD) based on the Questionnaire for Impulsive-compulsive Disorders in Parkinson's Disease form (QUIP).~* pregnant or lactating or planning on becoming pregnant in the next 18 weeks~* uncontrolled hypertension. Patients whose hypertension is controlled with medications are eligible.~* Concomitant monoamine oxidase (MAO) inhibitors or medicines contraindicated w/ MAO inhibitors not allowed

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rasagiline 1 mg (Type: EXPERIMENTAL): Participants took a 1 mg rasagiline tablet orally each day for 18 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants took a matching placebo tablet once daily for 18 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients with newly-diagnosed chronic-phase Ph-positive chronic myeloid leukaemia (maximum 3 months as of the diagnosis of the disease, with the date of the cytogenetic study regarded as such).~2. Age between 18 and 72 years (both included).~3. Performance status \< 2 on the ECOG scale (see Annex 3).~4. Secure written or oral informed consent in the presence of a witness and consent for biological samples (annexes 5 and 6).~Exclusion Criteria:~1. Criteria of acceleration or blastic crisis (see Annex 7).~2. When there is a compatible family donor in patients aged under 40 years or a non-relative donor in patients aged under 30 years (in whom allogenic transplant is still regarded as first-line treatment), the possibility of performing an allogenic transplant as first therapeutic option should be considered. In any case, as this aspect is still a matter of debate, it is left up to each group to take the relevant decision depending on the institution's policy.~3. Administration of other treatments before inclusion in the protocol (a maximum of 3 months of monotherapy with hydroxyurea is permitted).~4. Altered hepatic or renal function (SGOT, SGPT, total bilirubin and creatinine \> 1.5 times the upper limit of normality).~5. Uncontrolled diseases, such as thyroidal dysfunction, diabetes mellitus, angina pectoralis, serious heart failure (functional class III/IV of the New York Heart Association classification), neuropsychiatric infection or disease (see annex 15).~6. Positive serology for HIV.~7. Record of cancer in the last 5 years (barring basal cell skin carcinoma and cervical carcinoma in situ).~8. Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 72 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Physical Activity Outcomes After Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Veteran~* Planned unilateral total knee arthroplasty~Exclusion Criteria:~* Severe non-surgical limb pain (pain \>5/10 on non-surgical limb with walking)~* Unstable orthopedic, neurologic, or pulmonary condition that limits function~* Unstable cardiac condition~* Uncontrolled hypertension~* Uncontrolled diabetes~* Acute systemic infection~* Active cancer treatment~* Recent stroke (within 2 years)

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Physical Activity Behavior Intervention (Type: EXPERIMENTAL): A 12-week behavior change intervention that supplements conventional rehabilitation including: 10 telerehabilitation sessions, daily activity sensor use, education, self-monitoring, tailored feedback, barrier/facilitator identification, promotion of problem solving, action planning, and encouragement.
- Attention Control (Type: ACTIVE_COMPARATOR): Conventional rehabilitation with 10 telerehabilitation sessions that match the frequency and duration of the experimental arm. Attention control intervention provided as 10 telerehabilitation sessions of non-physical activity related education-only sessions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria~* Has a diagnosis of T2DM.~* Has HbA1c of 8.0% to 12.0%, inclusive, at Visit 1 and Visit 2.~* Treated with a stable dose of metformin ≥1500 mg/day for at least 2 months prior to Screening.~Exclusion criteria~* FPG ≥280 mg/dL (15.6 mmol/L).~* Serum calcitonin concentration ≥40 pg/mL (≥40 ng/L) at Visit 1 (Screening)~* Clinically significant abnormal free T4 values or patients needing initiation or adjustment of thyroid treatment according to the investigator.~* Abnormal thyroid stimulating hormone (TSH) value at Screening will be further evaluated by free T4.Patients with clinically significant abnormal free T4 values will be excluded.~* Known active proliferative retinopathy.~* History of, or currently have, acute or chronic pancreatitis, or have triglyceride concentrations ≥500 mg/dL (≥5.65 mmol/L) at Visit 1~* History or presence of inflammatory bowel disease or other severe GI diseases, particularly those which may impact gastric emptying, such as gastroparesis or pyloric stenosis.~* History of gastric bypass surgery or gastric banding surgery, or either procedure is planned during the time period of the study. Current use of gastric balloons is also excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide Once Weekly 2 mg and Dapagliflozin Once Daily 10 mg (Type: EXPERIMENTAL): None
- Exenatide Once Weekly 2 mg Alone (Type: EXPERIMENTAL): None
- Dapagliflozin Once Daily 10 mg Alone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Documented HIV-1 seropositive~* Not on HIV-1 antiretroviral therapy nor planning to initiate antiretroviral therapy during the study period~* Detectable HIV-1 plasma viral load~* HSV-2 seropositive as determined by western blot~* Not intending to move out of the area for the duration of study participation~* Willing and able to provide independent written informed consent~* Willing and able to undergo clinical evaluations~* Willing and able to take study drug as directed~* Willing and able to adhere to follow-up schedule~Exclusion Criteria:~* Known history of adverse reaction to acyclovir, valacyclovir, or famciclovir~* Planned open label use of acyclovir, valacyclovir, or famciclovir~* History of evidence of CMV disease~* Known medical history of seizures~* Known renal insufficiency, defined as serum creatinine greater than 1.5 mg/dl~* AST or ALT greater than 3 times upper limit of normal~* Hematocrit less than 30 %~* Neutropenia, defined as absolute neutrophil count less than 1000~* Thrombocytopenia, defined as platelet count less than 75,000~* History of thrombotic microangiopathy~* For women, pregnancy as confirmed by a urine pregnancy test~* Any other condition which, in the opinion of the principal investigator, may compromise the ability to follow study procedures and complete the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard-dose acyclovir (Type: ACTIVE_COMPARATOR): acyclovir 400 mg orally twice daily for 12 weeks.
- High-dose valacyclovir (Type: EXPERIMENTAL): valacyclovir 1000 mg orally twice daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men ages 18 to 45 years~* Reside in a randomly selected neighborhoods~* Report vaginal intercourse in the previous 3 months~* Have a photo identification~Exclusion Criteria:~* Plan to relocate from the area within the next 15 months

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- HIV/STD risk-reduction (Type: EXPERIMENTAL): Men Making a Difference HIV/STD Risk Reduction Intervention was designed to reduce sexual risk behaviors that increase risk of HIV and other sexually transmitted diseases.
- Health Promotion Control (Type: ACTIVE_COMPARATOR): Health Promotion Intervention was designed to increase physical activity, healthful diet, and other behaviors to reduce risk of noncommunicable diseases, including diabetes, hypertension, and cancers.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Concerta in Treating ADHD in Mothers of Children With ADHD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Mother:~* Have ADHD or problems paying attention and concentration themselves~* Have a child 6-12 years old with ADHD or possible ADHD~* Be the child's biological mother~Exclusion Criteria:~* Any CURRENT Axis I disorder (including major depression, psychosis, and substance use disorders) but with the exception of minor depressive or anxiety disorders~* Use of Anti-depressant medication~* Mothers with severe tics or Tourette's syndrome, a history of seizures or abnormal EEGs, high blood pressure, or narrowing or blockage of the GI tract~* Any women pregnant or brest-feeding

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of Bipolar I Disorder, Most recent episode Manic (296.4x), or Bipolar I Disorder, Most Recent Episode Depressed (296.5x), or Bipolar I Disorder, Most recent Episode Mixed (296.6x), with or without psychotic features, as defined by Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV)~* At least 1 manic, depressed, or mixed episode in the 2 years prior to the index episode.~* Able to understand and comply with the requirements of the study.~Exclusion Criteria:~* Diagnosis of an anxiety disorder as defined by DSM-IV, which was treated with medication within the past year.~* Known intolerance or lack of response to quetiapine fumarate or to the assigned mood stabilizer, as judged by the investigator.~* Previously randomized into this study or D1447C00126

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Routine IM Influenza Immunization and Administration by Jet-injector (Med-Jet H4™) in Healthy Young Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female adults~* 18 to 49 years of age~* body mass index (BMI) of ≥ 18 kg/m2 and ≤ 32 kg/m2~* Must be accessible by phone on a consistent basis and be available for the D21 blood draw~Exclusion Criteria:~* Any influenza vaccine during the 2016-2017 season~* significant acute or chronic, uncontrolled medical or neuropsychiatric illness~* confirmed or suspected immunosuppressive condition or immunodeficiency~* history of autoimmune disease, cancer, or treatment for cancer within 3 years of study vaccine administration~* Receipt of any investigational or non-registered product within 30 days prior to study enrolment~* receipt of systemic glucocorticoids at a dose exceeding 10 mg of prednisone per day, or equivalent, for more than 7 consecutive days or for 10 or more days in total within 1 month of vaccine administration~* any other cytotoxic or immunosuppressant drug or any globulin preparation within 3 months of vaccination~* blood transfusion within 90 days of study vaccination~* Although there is no known danger from influenza vaccination during pregnancy, pregnant women will be excluded since the efficacy of the Med-Jet delivery system is not yet known~* known drug or alcohol abuse will also be excluded.~Temporary Contraindications Following the resolution, in the opinion of the Investigator, of the following temporary conditions that constitute contraindications to administration of study vaccine, subjects may be enrolled in the study:~* Temperature ≥ 38.0 ºC within 24 hours prior to randomization.~* Acute cold symptoms such as upper respiratory tract infection symptoms, with or without fever, which typically resolve in 48 to 72 hours prior to randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Jet injector (Type: ACTIVE_COMPARATOR): 40 participants will receive Fluviral influenza vaccine using the Med-Jet H4
- IM injection (pre-filled syringe) (Type: ACTIVE_COMPARATOR): 20 participants will receive Fluviral influenza vaccine using pre-filled syringes for time-motion comparison to Med-Jet H4
- IM injection (multi-dose vial) (Type: ACTIVE_COMPARATOR): 20 participants will receive Fluviral influenza vaccine using a multi-dose vial for time-motion comparison to Med-Jet H4

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete